All-cause and cause-specific mortality assessment in patients receiving sodium glucose co-transporter-2 inhibitors
The American Journal of Medicine
•
August 01, 2026
SGLT2 inhibitors reduce cardiorenal deaths
SGLT2 inhibitors reduced cardiovascular and kidney-related deaths, but not overall deaths, in pooled trial data. *Systematic review and meta-analysis of RCTs; Level 1a.
- Level of evidence
- Level 1a
- DocG quality score
- 6.3 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
